Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Status:
Completed
Trial end date:
2018-02-05
Target enrollment:
Participant gender:
Summary
This is an open-label prospective community intervention trial to assess the impact of
community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws
bacterial skin infections.
Communities will be randomised to receive standard treatment for both yaws and scabies either
in parallel (site 1) or in sequence (site 2).
Treatment of yaws:
Single dose of Azithromycin (30mg/kg, max 2G).
Treatment of scabies:
Either an oral dose of Ivermectin (200μg/kg) or permethrin cream for those with a
contraindication to Ivermectin (WT<15kg, pregnant or breastfeeding women) given in 2 doses
7-14 days apart.
Investigators will complete a clinical and microbiological assessment of bacterial skin
disease at baseline and at 12 months to assess the impact of treatment on the prevalence of
bacterial infection and the emergence of antimicrobial resistance.
Primary Outcome
1. Difference in the change in prevalence of impetigo between baseline and 12- months
between the parallel and the sequential treatment arms.
Secondary Outcomes
2. Change in the proportion of swab samples from which S. pyogenes is cultured between
baseline and follow-up in the two arms
3. The proportion of samples from which a drug-resistant isolate of S.pyogenes is cultured
in the two arms
Phase:
Phase 4
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborators:
Atoifi Adventist Hospital, Solomon Islands Kirby Institute Murdoch Childrens Research Institute